Skip to main content
SpringerLink
Log in

Erfahrungen mit Etoposid in der Therapie der Non-Hodgkin-Lymphome

  • Chapter
Etoposid (VP 16-213) in der Therapie maligner Erkrankungen

  • 18 Accesses

Zusammenfassung

Die Non-Hodgkin-Lymphome (NHL) gehören zu den Neoplasien, denen aufgrund der in den letzten Jahren erzielten Fortschritte in Diagnostik und Therapie besondere Aufmerksamkeit geschenkt wird. Durch eine Intensivierung der Therapie hat sich die Prognose vor allem der Non-Hodgkin-Lymphome hohen Malignitätsgrades entscheidend gebessert. Wesentlichen Anteil hatte hierbei die Behandlung mit einem Polychemotherapieschema bestehend aus Cyclophosphamid, Hydroxy-Daunomycin (Adriamycin), Oncovin (Vincristin) und Prednison (CHOP), das bei 48 bis 68% der Patienten zu Vollremissionen führt (1, 9, 21, 25, 26). Ähnliche Polychemotherapieschemata wie CHOP-Bleo, BACOP, HOP, COPP, COMLA etc. führen zu vergleichbar hohen Vollremissionsraten (10, 32). Die Uberlebenskurven von Patienten mit diffus-histiozytären NHL nach CHOP-Behandlung bilden nach 24 Monaten ein Plateau bei 40 bis 50% aller behandelten Patienten (1, 9, 21, 25, 26). Da Rezidive nach diesem Zeitpunkt selten sind (1, 14), kann bei etwa 40% der Patienten mit einer Heilung gerechnet werden.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 44.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 59.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Armitage, J. O., Corder, M. P., Leimer, J. T., Dick, F. R., Eliiott, T. F.: Advanced diffuse histiocytic lymphoma treated with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) without maintenance therapy. Cancer Treat. Rep. 64, 649–654 (1980).

    PubMed  CAS  Google Scholar 

  2. Arnold, A. M.: Podophyllotoxin derivative VP 16-213. Cancer Chemother. Pharmacol. 3, 71–80 (1979).

    Article  PubMed  CAS  Google Scholar 

  3. Bender, R. A., Anderson, T., Fischer, R. T., et al.: The activity of the epipodophyllotoxin VP16 in the treatment of combination chemotherapy resistant non-Hodgkin’s lymphoma. Amer. J. Hematol. 5, 203–209 (1978).

    Article  CAS  Google Scholar 

  4. Bender, R. A., DeVita, V. T., jr.: Non-Hodgkin’s lymphoma. In: Randomized Trials in Cancer, a Critical Review by Sites (Staquet, M.J., (Hrsg.), S. 77. New York: Raven Press. 1978.

    Google Scholar 

  5. Cabanillas, F., Rodriguez, V., Bodey, G. P.: Ifosfamide, methotrexate, and vincristine (IMV) combination chemotherapy as secondary treatment for patients with malignant lymphoma. Cancer Treat. Rep. 64, 933–937 (1980).

    PubMed  CAS  Google Scholar 

  6. Cabanillas, F., Hagemeister, F. B., Bodey, G. P., Freireich, E. J.: IMVP 16, an effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy. In Druck.

    Google Scholar 

  7. Cecil, J. W., Quagliana, J. M., Coltman, C. A., Al-Sarraf, M., Thigpen, T., Groppe, C. W.: Evaluation of VP 16-213 in malignant lymphoma and melanoma. Cancer Treat. Rep. 62, 801–803 (1978).

    PubMed  CAS  Google Scholar 

  8. Chard, P. L., Krivit, W., Bleyer, W. A., Hammond, D.: Phase II study of VP-16–213 in childhood malignant disease: A children’s cancer study group report. Cancer Treat. Rep. 63, 1755–1759 (1979).

    PubMed  Google Scholar 

  9. Comella, P., Abatz, G., Comella, G., Bruni, G. S., Zarilli, D., Pergola, M.: Combination chemotherapy with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP) for non-Hodgkin’s lymphomas with unfavourable histology: Preliminary results. Tumori 66, 749–756 (1980).

    PubMed  CAS  Google Scholar 

  10. DeVita, V. T., Jr., Hellman, S.: Hodgkin’s disease and the non-Hodgkin’s lymphoma. In: Cancer — Principles and Practice of Oncology (DeVita, V. T., Jr., Hellmann, S., Rosenberg, S. A., Hrsg.), S. 1331–1401. Philadelphia-Toronto: Lippincott. 1982.

    Google Scholar 

  11. Dombernowsky, P., Nissen, N. I., Larsen, V.: Clinical investigation of a new podophyllum derivative, epipodophyllotoxin 4’-demethyl-9-(4,5,0–2- thenylidene-β-D-glucopyranoside) (NSC-122819), in patients with malignant lymphomas and solid tumors. Cancer Chemother. Rep. 56, 71–82 (1972).

    PubMed  CAS  Google Scholar 

  12. European Organization for Research on the Treatment of Cancer, Clinical Screening Group: Epipodophyllotoxin VP 16-213 in treatment of acute leukaemias, haematosarcomas and solid tumors. Brit. Med. J. 3, 199–202 (1973).

    Article  Google Scholar 

  13. Falkson, G., Van Dyk, J. J., van Eden, E. B., van der Merve, A. M., van den Bergh, J. A., Falkson, H. C.: A clinical trial of the oral form of 4’- demethyl-epipodophyllotoxin-β-D-l-ethylidene glucoside (NSC 141540) VP 16-213. Cancer 35, 1141–1144 (1975).

    Article  PubMed  CAS  Google Scholar 

  14. Fisher, R. L, DeVita, V. T., Hubbard, S. M., Longo, D. L., Wesley, R., Chabner, B. A., Young, R. C.: Diffuse aggressive lymphomas: Increased survival after alternating flexible sequences of ProMACE and MOPP chemotherapy. Ann. Intern. Med. 98, 304–309 (1983).

    PubMed  CAS  Google Scholar 

  15. Hellriegel, K. P., Fülle, H. H., Raettig, R.: Etoposid-Dosisfindung im Rahmen der Kombination Cyclophosphamid, Adriamycin, Etoposid und Prednison für die Behandlung von Non-Hodgkin-Lymphomen hohen Malignitätsgrades. (Unveröffentlichte Ergebnisse.)

    Google Scholar 

  16. Isseil, B. F., Crooke, S. T.: Etoposide (VP 16-213). Cancer Treat. Rev. 6, 107–124 (1979).

    Article  Google Scholar 

  17. Jacobs, P., King, H., Cassidy, F., Dent, D.: The treatment of diffuse lymphocytic lymphoma (large cell) with VP 16-213. Proc. Amer. Ass. Cancer Res. & Amer. Soc. clin. Oncol. 20, 289, AACR Abstr. 1179 (1979).

    Google Scholar 

  18. Jacobs, P., King, H. S., Cassidy, F., Dent, D. M., Harrison, T.: VP 16-213 in the treatment of stage III and IV diffuse lymphocytic lymphoma of the large cell (histiocytic) variety: An interim report. Cancer Treat. Rep. 65, 987–993 (1981).

    PubMed  CAS  Google Scholar 

  19. Jacobs, P., King, H. S., Dent, D.: The epipodophyllotoxin VP 16-213 as an effective agent in the treatment of patients with diffuse large cell lymphoma. Proc. Ist Intern. Conf. on Malignant Lymphoma, Lugano, September 2–5, 1981, Abstr. No. 59.

    Google Scholar 

  20. Jacobs, P., King, H. S., Sealy, G. R. H.: Epipodophyllotoxin (VP 16-213) in the treatment of diffuse histiocytic lymphoma. S. Afr. Med. J. 49, 483–485 (1975).

    Google Scholar 

  21. Jones, S. E., Grozea, P. N., Metz, E. N., Hant, A., Stephens, R. L., Morrison, F. S., Butlery J. J., Byrne, G. E., Moon, T. E., Fisher, R., Haskinsy C. L., Coltman, C. A., Jr.: Superiority of adriamycin-containing combination chemotherapy in the treatment of diffuse lymphoma — a Southwest Oncology Group Study. Cancer 43, 417–425 (1979).

    Article  PubMed  CAS  Google Scholar 

  22. Lau, M. E., Hansen, H. H., Nissen, N. I., Pedersen, H.: Phase I trial of a new form of an oral administration of VP 16-213. Cancer Treat. Rep. 63, 485–587 (1979).

    PubMed  CAS  Google Scholar 

  23. Mathe, G., Schwarzenberg, L., Pouillart, P., Oldham, R., Weiner, R., Jasmin, C., Rosenfeld, C., Hayat, M., Misset, J. L., Musset, M., Schneider, M., Amiel, J. L., De Vassal, F.: Two epipodophyllotoxin derivatives, VM 26 and VP 16-213, in the treatment of leukemias, hematosarcomas, and lymphomas. Cancer 34, 985–992 (1974).

    Article  PubMed  CAS  Google Scholar 

  24. Mathe, G., Schwarzenberg, L., Pouillart, P., Weiner, R., Oldham, R., Jasmin, C., Rosenfeld, C., Hayat, M., Schneider, M., Amiel, J. L., Ce’Ora, B., Stereco-Musset, M., De Vassal, F.: Acute leukaemia and various hematosarcomas. Trial treatment with 4-demethyl-epipodophyllo- toxin-beta-D-ethylidene glucoside VP 16-213. Nouv. Presse Med. 3, 521–524 (1974).

    PubMed  CAS  Google Scholar 

  25. McKelvey, E. M.: Review of CHOP-HOP combination chemotherapy in malignant lymphoma. Proc. Amer. Ass. Cancer Res. & Amer. Soc. Clin. Oncol. 19, 415 (1978).

    Google Scholar 

  26. McKelvey, E. M., Gottlieb, J. A., Wilson, H. E., Hant, A., Talley, R. W., Stephens, R., Lane, M., Gamble, J. F., Jones, S. F., Grozea, P. N., Gutterman, J., Coltman, C., Jr., Moon, T. E.: Hydroxyldaunomycin (adriamycin) combination chemotherapy in malignant lymphoma. Cancer 38, 1484–1493 (1976).

    Article  PubMed  CAS  Google Scholar 

  27. Nissen, N. L, Dombernowsky, P., Hansen, H. H., Larsen, V.: Phase I clinical trial of an oral Solution of VP 16-213. Cancer Chemother. Rep. 60, 943–944 (1976).

    CAS  Google Scholar 

  28. Nissen, N. I., Larsen, V., Pedersen, H., Thomsen, K.: Phase I clinical trial of a new antitumor agent, 4’-demethyl-epipodophyllotoxin 9-(4,6–0-ethy- lidene-β-D-glucopyranoside) (NSC 141540), VP 16-213. Cancer Chemother. Rep. 56, 769–777 (1972).

    PubMed  CAS  Google Scholar 

  29. Nissen, N. I., Pajak, T. F., Leone, L. A., Bloomfield, C. D., Kennedy, B. J., Ellison, R. R., Silver, R. T., Weiss, R. B., Cuttner, J., Falkson, G., Kung, F., Bergevin, P. R., Holland, J. F: Clinical trial of VP 16-213 (NSC 141540) i.v. twice weekly in advanced neoplastic disease. Cancer 45 232–235 (1980).

    Article  PubMed  CAS  Google Scholar 

  30. Radice, R. A, Zfowz, P. A, M, £). C: Therapeutic trials with VP-16–213 and VM-26: active agents in small cell lung cancer, non- Hodgkin’s lymphomas, and other malignancies. Cancer Treat. Rep. 63, 1231–1239 (1979).

    CAS  Google Scholar 

  31. Schmoll, H. J., Niederle, N., Achterrath, W.: Etoposid (VP 16-213) — Eine antineoplastische Substanz aus der Reihe der Podophyllotoxine. Klin. Wschr. 59, 1177–1188 (1981).

    Article  PubMed  CAS  Google Scholar 

  32. Sweet, D. L., Golomb, H. M.: The treatment of histiocytic lymphoma. Sem. Oncol. 7, 302–309 (1980).

    CAS  Google Scholar 

  33. Taylor, R. E., McElwain, T. J., Barrett, A, Peckham, M. J.: Etoposide as a single agent in relapsed advanced lymphomas. A phase II study. Cancer Chemother. Pharmacol. 7, 175–177 (1982).

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Interne Klinik, Krankenhaus Moabit, Berlin, Deutschland

    Prof. Dr. K. P. Hellriegel

Authors
  1. Prof. Dr. K. P. Hellriegel
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. I. Medizinischen Universitätsklinik, Wien, Austria

    Josef Schwarzmeier (Oberarzt) & Erwin Deutsch (Vorstand) (Oberarzt) &  (Vorstand)

  2. Gemeinsame Institutseinrichtung für Epidemiologie der Neoplasmen, Universität Wien, Austria

    Karl Karrer

Rights and permissions

Reprints and permissions

Copyright information

© 1984 Springer-Verlag/Wien

About this chapter

Cite this chapter

Hellriegel, K.P. (1984). Erfahrungen mit Etoposid in der Therapie der Non-Hodgkin-Lymphome. In: Schwarzmeier, J., Deutsch, E., Karrer, K. (eds) Etoposid (VP 16-213) in der Therapie maligner Erkrankungen. Springer, Vienna. https://doi.org/10.1007/978-3-7091-8755-5_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-8755-5_8

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-211-81801-5

  • Online ISBN: 978-3-7091-8755-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation